Active Ingredient History
Enfortumab vedotin, sold under the brand name Padcev, is an antibody-drug conjugate used for the treatment of urothelial cancer. It is a nectin-4-directed antibody and microtubule inhibitor conjugate. Enfortumab refers to the monoclonal antibody part, and vedotin refers to the payload drug (MMAE) and the linker. Wikipedia
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Carcinoma, Transitional Cell (approved 2019)
Adenocarcinoma (Phase 2)
Carcinoma in Situ (Phase 1)
Carcinoma, Transitional Cell (Phase 3)
Medical Oncology (Phase 1)
Neoplasms (Phase 2/Phase 3)
Pancreatic Neoplasms (Phase 2)
Penile Neoplasms (Phase 2)
Ureteral Neoplasms (Phase 3)
Urethral Neoplasms (Phase 2)
Urinary Bladder Neoplasms (Phase 3)
Urologic Neoplasms (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
